CAC
MCRB icon

Cowen and Company’s Seres Therapeutics MCRB Stock Holding History

Cowen and Company’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-625
Closed -$99.3K – 720
2021
Q3 		$87K Buy
+625
New +$122K ﹤0.01% 338

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cowen and Company's MCRB Position: Q4 2021 in Review

Cowen and Company sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 625 shares — an estimated $99.3K sold.

Cowen and Company first reported a position in MCRB in Q3 2021 and held it in 1 quarter. The position peaked at $87K in Q3 2021. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • Cowen and Company reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cowen and Company sold 625 Seres Therapeutics shares in Q4 2021, an estimated $99.3K.
  • Cowen and Company first reported a position in Seres Therapeutics in Q3 2021 and held it in 1 quarter.
  • Cowen and Company's Seres Therapeutics position peaked at $87K in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.